questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Effets physiologiques des médicaments
Agents neuromédiateurs
Agents cholinergiques
Inhibiteurs de la libération d'acétylcholine
Inhibiteurs de la libération d'acétylcholine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Diagnostic
Acétylcholine
Neurologie
Tests électromyographiques
Acétylcholine
Analyse sanguine
Faiblesse musculaire
Fatigue
Acétylcholine
Antécédents médicaux
Acétylcholine
Évaluation clinique
Imagerie cérébrale
Pathologies neurologiques
Acétylcholine
Symptômes
5
Faiblesse musculaire
Fatigue
Coordination
Troubles de la mémoire
Concentration
Acétylcholine
Difficultés respiratoires
Acétylcholine
Système respiratoire
Âge
Symptômes
Acétylcholine
Nausées
Troubles gastro-intestinaux
Acétylcholine
Prévention
5
Prévention
Mode de vie sain
Acétylcholine
Alimentation équilibrée
Antioxydants
Acétylcholine
Exercice physique
Fonction musculaire
Acétylcholine
Stress
Symptômes
Acétylcholine
Contrôles réguliers
Surveillance
Acétylcholine
Traitements
5
Médicaments anticholinestérasiques
Thérapies physiques
Acétylcholine
Efficacité des traitements
Qualité de vie
Acétylcholine
Effets secondaires
Nausées
Acétylcholine
Rééducation physique
Renforcement musculaire
Acétylcholine
Traitements personnalisés
Acétylcholine
Médecine personnalisée
Complications
5
Complications
Troubles respiratoires
Crises musculaires
Hospitalisations
Surveillance
Acétylcholine
Risque de décès
Inhibition sévère
Acétylcholine
Complications réversibles
Traitement approprié
Acétylcholine
Gestion des complications
Approche multidisciplinaire
Acétylcholine
Facteurs de risque
5
Facteurs de risque
Maladies auto-immunes
Antécédents familiaux
Âge avancé
Facteurs de risque
Acétylcholine
Médicaments
Risque
Acétylcholine
Mode de vie sédentaire
Mauvaise alimentation
Acétylcholine
Infections virales
Risque
Acétylcholine
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la libération d'acétylcholine : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la libération d'acétylcholine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la libération d'acétylcholine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-06",
"dateModified": "2025-05-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la libération d'acétylcholine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Agents cholinergiques",
"url": "https://questionsmedicales.fr/mesh/D018678",
"about": {
"@type": "MedicalCondition",
"name": "Agents cholinergiques",
"code": {
"@type": "MedicalCode",
"code": "D018678",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.577.120"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la libération d'acétylcholine",
"alternateName": "Acetylcholine Release Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D065087",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ikunobu Muramatsu",
"url": "https://questionsmedicales.fr/author/Ikunobu%20Muramatsu",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan."
}
},
{
"@type": "Person",
"name": "Junsuke Uwada",
"url": "https://questionsmedicales.fr/author/Junsuke%20Uwada",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan."
}
},
{
"@type": "Person",
"name": "Kiyonao Sada",
"url": "https://questionsmedicales.fr/author/Kiyonao%20Sada",
"affiliation": {
"@type": "Organization",
"name": "Division of Genomic Science and Microbiology, School of Medicine, University of Fukui, Eiheiji, Fukui, Japan."
}
},
{
"@type": "Person",
"name": "Takayoshi Masuoka",
"url": "https://questionsmedicales.fr/author/Takayoshi%20Masuoka",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan."
}
},
{
"@type": "Person",
"name": "Takashi Yazawa",
"url": "https://questionsmedicales.fr/author/Takashi%20Yazawa",
"affiliation": {
"@type": "Organization",
"name": "Division of Cellular Signal Transduction, Department of Biochemistry, Asahikawa Medical University, Asahikawa, Hokkaido, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Estimating Perfusion Deficits in Acute Stroke Patients Without Perfusion Imaging.",
"datePublished": "2022-07-22",
"url": "https://questionsmedicales.fr/article/35866426",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/STROKEAHA.121.038101"
}
},
{
"@type": "ScholarlyArticle",
"name": "Untargeted metabolomics of perfusate and their association with hypothermic machine perfusion and allograft failure.",
"datePublished": "2022-12-20",
"url": "https://questionsmedicales.fr/article/36549364",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.kint.2022.11.020"
}
},
{
"@type": "ScholarlyArticle",
"name": "On Normothermic Regional Perfusion.",
"datePublished": "2024-07-19",
"url": "https://questionsmedicales.fr/article/39031550",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/hast.1601"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cerebral perfusion in type 2 diabetes mellitus: A preliminary study with MR perfusion.",
"datePublished": "2023-06-07",
"url": "https://questionsmedicales.fr/article/37327716",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clineuro.2023.107816"
}
},
{
"@type": "ScholarlyArticle",
"name": "Relative Lung Perfusion on Ventilation-Perfusion Scans After Double Lung Transplant.",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37291709",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/TP.0000000000004683"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Effets physiologiques des médicaments",
"item": "https://questionsmedicales.fr/mesh/D045505"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents neuromédiateurs",
"item": "https://questionsmedicales.fr/mesh/D018377"
},
{
"@type": "ListItem",
"position": 6,
"name": "Agents cholinergiques",
"item": "https://questionsmedicales.fr/mesh/D018678"
},
{
"@type": "ListItem",
"position": 7,
"name": "Inhibiteurs de la libération d'acétylcholine",
"item": "https://questionsmedicales.fr/mesh/D065087"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la libération d'acétylcholine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la libération d'acétylcholine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la libération d'acétylcholine",
"description": "Comment diagnostiquer une inhibition de l'acétylcholine ?\nQuels tests sont utilisés pour évaluer l'acétylcholine ?\nQuels symptômes indiquent une inhibition d'acétylcholine ?\nLes antécédents médicaux sont-ils importants ?\nPeut-on utiliser l'imagerie pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Perfusion#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la libération d'acétylcholine",
"description": "Quels sont les symptômes courants d'une inhibition ?\nL'inhibition affecte-t-elle la cognition ?\nY a-t-il des symptômes respiratoires associés ?\nLes symptômes varient-ils selon l'âge ?\nPeut-on avoir des symptômes digestifs ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Perfusion#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la libération d'acétylcholine",
"description": "Peut-on prévenir l'inhibition d'acétylcholine ?\nL'alimentation joue-t-elle un rôle ?\nL'exercice physique est-il bénéfique ?\nLe stress peut-il aggraver l'inhibition ?\nDes contrôles réguliers sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Perfusion#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la libération d'acétylcholine",
"description": "Quels traitements sont disponibles pour l'inhibition ?\nLes traitements sont-ils efficaces ?\nY a-t-il des effets secondaires aux traitements ?\nLa rééducation est-elle recommandée ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Perfusion#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la libération d'acétylcholine",
"description": "Quelles complications peuvent survenir ?\nL'inhibition peut-elle entraîner des hospitalisations ?\nY a-t-il un risque de décès ?\nLes complications sont-elles réversibles ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Perfusion#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la libération d'acétylcholine",
"description": "Quels sont les facteurs de risque d'inhibition ?\nL'âge est-il un facteur de risque ?\nLes médicaments peuvent-ils influencer le risque ?\nLe mode de vie affecte-t-il le risque ?\nLes infections virales sont-elles un risque ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Perfusion#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inhibition de l'acétylcholine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests neurologiques et l'évaluation des symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'acétylcholine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests électromyographiques et des analyses sanguines peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une inhibition d'acétylcholine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la faiblesse musculaire et la fatigue peuvent indiquer une inhibition."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux sont-ils importants ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents médicaux aident à identifier des causes potentielles d'inhibition."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie cérébrale peut aider à exclure d'autres pathologies neurologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants d'une inhibition ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent faiblesse musculaire, fatigue, et troubles de la coordination."
}
},
{
"@type": "Question",
"name": "L'inhibition affecte-t-elle la cognition ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des troubles de la mémoire et de la concentration."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes respiratoires associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des difficultés respiratoires peuvent survenir en cas d'inhibition sévère."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être plus prononcés chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes digestifs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des nausées et des troubles gastro-intestinaux peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'inhibition d'acétylcholine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures préventives incluent un mode de vie sain et la gestion du stress."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée riche en antioxydants peut soutenir la santé neuronale."
}
},
{
"@type": "Question",
"name": "L'exercice physique est-il bénéfique ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la fonction musculaire et nerveuse."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver l'inhibition ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut exacerber les symptômes d'inhibition d'acétylcholine."
}
},
{
"@type": "Question",
"name": "Des contrôles réguliers sont-ils nécessaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de surveiller l'évolution et d'ajuster les traitements."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'inhibition ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments anticholinestérasiques et des thérapies physiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent améliorer les symptômes et la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des nausées et des crampes peuvent survenir."
}
},
{
"@type": "Question",
"name": "La rééducation est-elle recommandée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la rééducation physique peut aider à renforcer les muscles et améliorer la fonction."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles respiratoires et des crises musculaires."
}
},
{
"@type": "Question",
"name": "L'inhibition peut-elle entraîner des hospitalisations ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des cas graves peuvent nécessiter une hospitalisation pour surveillance."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de décès ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans des cas extrêmes, l'inhibition sévère peut entraîner des risques mortels."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'inhibition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des maladies auto-immunes, des infections et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé est un facteur de risque pour les troubles de la libération d'acétylcholine."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils influencer le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent augmenter le risque d'inhibition d'acétylcholine."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales peuvent déclencher des troubles de la libération d'acétylcholine."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 01/05/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Division of Genomic Science and Microbiology, School of Medicine, University of Fukui, Eiheiji, Fukui, Japan.
Kimura Hospital, Awara, Fukui, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
3 publications dans cette catégorie
Affiliations :
Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Division of Cellular Signal Transduction, Department of Biochemistry, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
3 publications dans cette catégorie
Affiliations :
Division of Genomic Science and Microbiology, School of Medicine, University of Fukui, Eiheiji, Fukui, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
3 publications dans cette catégorie
Affiliations :
Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Division of Cellular Signal Transduction, Department of Biochemistry, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Division of Cellular Signal Transduction, Department of Biochemistry, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Pharmacology, School of Medicine, Tokai University, Isehara 259-1193, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Tokyo Dental College, Misaki-cho, Chiyoda-ku, Tokyo 101-0061, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Neuroimmune Signaling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia (D.S.L., E.V.K., I.A.I., N.S.E., N.D.T., E.N.S., E.Y.T., A.E.S., D.S.K., I.E.K., V.I.T.); Department of Neurobiology, Hellenic Pasteur Institute, Athens, Greece (M.Z., S.J.T.); Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russia (I.E.K.); Institute of Chemistry and Molecular Engineering, Agricultural University of Georgia, Kakha Bendukidze University Campus, Tbilisi, Georgia (R.K., N.Z., I.I.); and PhysBio of MePhI, Moscow, Russia (V.I.T.) victortsetlin3f@gmail.com.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan. Electronic address: torukawa@ncvc.go.jp.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiac Physiology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiac Physiology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiac Physiology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Kazan Institute of Biochemistry and Biophysics FRC Kazan Scientific Center of RAS, PB 30, Kazan 420111, Russia. Electronic address: ellyab@mail.ru.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
a Department of Pharmacy , Peking University People's Hospital , Beijing 100730 , China.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
2 publications dans cette catégorie
Affiliations :
b Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation, Department of Clinical Pharmacology , Beijing Hospital , Bejing 100044 , China.
Publications dans "Inhibiteurs de la libération d'acétylcholine" :
Perfusion weighted imaging (PWI) is critical for determining whether stroke patients presenting in an extended time window are candidates for mechanical thrombectomy. However, PWI is not always availa...
The National Institutes of Health (NIH) FHV score was developed to quantify the burden of FHV and applied to magnetic resonance imaging scans of stroke patients with fluid-attenuated inversion recover...
There were 101 patients included in the analysis, of whom 78% had a perfusion deficit detected on PWI with a mean lesion volume of 47 (±59) mL. The NIH-FHV score was strongly associated with the PWI l...
The NIH-FHV score provides an estimate of the PWI lesion volume and, when combined with diffusion weighted imaging, may be helpful when trying to determine whether there is a clinically relevant diffu...
Although hypothermic machine perfusion (HMP) is associated with improved kidney graft viability and function, the underlying biological mechanisms are unknown. Untargeted metabolomic profiling may ide...
This letter responds to the article "Neither Ethical nor Prudent: Why Not to Choose Normothermic Regional Perfusion," by Adam Omelianchuk et al., in the July-August 2024 issue of the Hastings Center R...
Type 2 diabetes mellitus (T2DM) is associated with altered cerebral vasoreactivity, cognitive impairment, and functional decline. Magnetic Resonance (MR) perfusion can be used to assess cerebral blood...
The study included 52 patients diagnosed with T2DM and 39 healthy individuals. The diabetic patients were classified into three groups (PRP: proliferative retinopathy, NPRP: non-proliferative retinopa...
The comparison between the T2DM group and the control group revealed that rCBF values of bilateral frontal lobes, cingulate gyrus, medial temporal lobe, thalami and right occipital lobe were measured ...
Regional hypoperfusion was encountered in most of the lobes in the T2DM group when compared with the healthy group. However, in terms of rCBF values, there was no significant difference among the thre...
Pulmonary blood flow can be assessed on ventilation-perfusion (VQ) scan with relative lung perfusion, with a 55% to 45% (or 10%) right-to-left differential considered normal. We hypothesized that wide...
We conducted a retrospective cohort study on all patients who underwent double-lung transplant in our program between 2005 and 2016, identifying patients with a wide perfusion differential of >10% on ...
Of 340 patients who met inclusion criteria, 169 (49%) had a relative perfusion differential of ≥ 10% on a 3-mo VQ scan. Patients with increased perfusion differential had increased risk of death or re...
Wide lung perfusion differential was common after lung transplant in our cohort and associated with increased risk of death, poor lung function, and CLAD onset. The nature of this abnormality and its ...
Although COVID-19 infection is associated with the increased risk of pulmonary thromboembolism (PTE), COVID-19 pulmonary lesions cause ventilation-perfusion (V/Q) patterns other than PTE. Although ext...
This article describes fabrication of a customizable bioreactor, which comprises a perfusion system and coverslip-based tissue culture chamber that allow centimeter-scale vascularized or otherwise can...
We aimed at examining both the incidence and extent of different lung perfusion abnormalities as well as the relationship between them on Tc-99m macroaggregated albumin (MAA) perfusion-only SPECT/CT s...
Ninety-one patients (71.4 ± 13.9 years; range: 29-98 years, median age: 74 years; 45 female and 46 male) with confirmed SARS-CoV-2 virus infection were included in this retrospective study. After perf...
Moderately severe parenchymal lesions were detected in 87 (95.6%) patients. Although, 50 (54.95%) patients were depicted to have MM lesions, the whole patient cohort was mildly affected by this abnorm...
Heterogeneous perfusion abnormalities were found in most of COVID-19 patients: parenchymal lesions with normal, decreased or increased perfusion and perfusion defects in healthy lung areas. These phen...
Liver transplantation is the only chance of cure for people with end-stage liver disease and some people with advanced liver cancers or acute liver failure. The increasing prevalence of these conditio...
To evaluate the effects of different methods of machine perfusion (including hypothermic oxygenated machine perfusion (HOPE), normothermic machine perfusion (NMP), controlled oxygenated rewarming, and...
We used standard, extensive Cochrane search methods. The latest search date was 10 January 2023....
We included randomised clinical trials which compared different methods of machine perfusion, either with each other or with SCS. Studies comparing HOPE via both hepatic artery and portal vein, or via...
We used standard Cochrane methods. Our primary outcomes were 1. overall participant survival, 2. quality of life, and 3. serious adverse events. Secondary outcomes were 4. graft survival, 5. ischaemic...
We included seven randomised trials (1024 transplant recipients from 1301 randomised/included livers). All trials were parallel two-group trials; four compared HOPE versus SCS, and three compared NMP ...
In situations where the decision has been made to transplant a liver donated after circulatory death or donated following brain death, end-ischaemic HOPE will provide superior clinically relevant outc...
The field of organ transplantation has been facing the problem of organ shortage for several years. It is even more crucial since the number of patients on the waiting list is growing steadily. There ...